A- A A+

Bayern. Interview: „Letztlich empfahl der Anstaltsarzt meinem Bruder, sich im Hof Drogen zu besorgen“

Claudia Jaworski hat ihrem heroinabhängigen Bruder Substitutionsmittel ins Gefängnis gebracht, weil ihm in Haft die Behandlung verweigert wurde – und steht nun selbst vor Gericht. Aus einer besorgten Schwester wurde eine Aktivistin. (Deutsche AIDS-Hilfe, hiv-magazin, 14.06.2021)


Substitution in Haft: Für eine wissenschaftlich-basierte Substitutionspraxis in bayerischen Haftanstalten

Positionspapier von: AG Aids&Haft in Bayern, AIDS-HilfeNürnberg-Erlangen-Fürth, Akzepte.V.–Bundesverband für akzeptierende Drogenarbeit und humane Drogenpolitik, Augsburger Aids-Hilfe, Caritasverband für die Diözese Augsburg e.V., Condrobs e.V. Deutsche Aidshilfe, Bayerische AIDS Stiftung, Verein zur Gesundheitsförderung e.V., Dick und Dünn Nürnberg e.V.-Fachberatung bei Essstörungen –Jugendberatung bei Essstörungen, Drogenhilfe Schwaben gGmbH, Dr. Thomas Galli für die Deutsche Gesellschaft zur humanen Fortentwicklung des Strafrechts, Extra e.V.-Suchthilfe für Frauen und Angehörige, MünchnerAIDS-Hilfe, Prope.V.–Drogennotdienst München L43, Strafvollzugsarchiv e.V.–Strafvollzugsarchiv an der Fachhochschule Dortmund, Therapieverbund Sucht-Caritasverband der Erzdiözese München und Freising e.V.

München im Juni 2021



Below you will find information and resources to help you advocate for policies to improve addiction prevention, treatment, and recovery and remission in correctional settings. (ASAM – American Society of Addiction Medicine, 2021)


USA. ‘We were blown away to see the success’: Kane County Jail drug treatment program slashes post-incarceration overdoses

(…) The jail has a voluntary in-house drug treatment program that includes a still-rare feature: Inmates who are addicted to heroin, OxyContin and other opioids can receive buprenorphine, a medication that is itself an opioid and can stave off withdrawal, lessen drug cravings and protect against overdose. (Chicago Tribune, USA, 23.04.2021)


Behandlung opioidabhängiger Inhaftierter - Einstellungen und Behandlungspraxis des medizinischen Personals in bayerischen Justizvollzugsanstalten

Maren Weiss, Kerstin Geißelsöder, Maike Breuer, Norbert Wodarz

Das Gesundheitswesen, March 2021, DOI: 10.1055/a-1399-9286



USA. Exclusive: ACLU Sues NY County Over Methadone Access in Prison

The New York Civil Liberties Union (NYCLU) and American Civil Liberties Union (ACLU) filed a lawsuit against Jefferson County in Upstate New York on April 5. It seeks to compel the Jefferson County Correctional Facility to provide access to methadone treatment for opioid use disorder (OUD). (Filter, USA, 05.04.2021)


USA. Initiating methadone in jail: Is it cost effective?

Medications for opioid use disorder (e.g., methadone, Suboxone) may be particularly useful in jails and prisons because of their ability to reduce overdose risk after release. However, few studies have looked at the cost-effectiveness of such services, meaning that the benefits and use of services are worth the financial resources needed to provide them. Cost-effectiveness studies help to inform the utility and feasibility of expanding services nationally. In this study, the researchers evaluated the cost and cost-effectiveness of two methadone treatment interventions to produce negative drug tests one year after release. Results showed that methadone treatment provided along with services that facilitate community-based treatment navigation, akin to “recovery coaching”, appear to be the most cost-effective option. (Recovery Research Institute, USA, 22.03.2021)


"My first 48 hours out": drug users' perspectives on challenges and strategies upon release from prison. 

Jamin D, Vanderplasschen W, Sys O, Jauffret-Roustide M, Michel L, Trouiller P, Neisa A, Homen M, Mendes V, Stöver H. 

Harm Reduct J. 2021 Mar 12;18(1):32. doi: 10.1186/s12954-021-00480-w. PMID: 33712032; PMCID: PMC7953692.


USA. Woman who sued DuPage County to receive methadone in jail as treatment for opioid addiction will get her meds

DuPage County officials agreed to provide methadone to a recovering opioid user who is serving a month in jail, federal court records indicate.

Christine Finnigan, 53, sued the county last month for an assurance she could receive her medication once she entered jail to serve a 30-day sentence for drunken driving. She has been on methadone since 2019 to help her combat a long-standing opioid addiction. (Chicago Tribune, USA, 26.02.2021)


Integrating episodes of imprisonment and the cascade of care for opioid use disorder. 

Cossar, R. D., Stewart, A. C., Winter, R., Curtis, M., Dietze, P. M., Ogloff, J. R. P., and Stoove, M. (2021)

Addiction, 116: 427– 428. doi.org/10.1111/add.15245.


USA. Judge Grants Class Action Status to Methadone-Taper Jail Lawsuit

A federal judge has paved the way for a case against a methadone-taper policy at Cook County Jail, Illinois to proceed as a class action lawsuit. (Filter, USA, 07.12.2020)


Fifteen years of heroin-assisted treatment in a Swiss prison—a retrospective cohort study. 

Liebrenz, M., Gamma, A., Buadze, A. et al.

Harm Reduct J 17, 67 (2020). doi.org/10.1186/s12954-020-00412-0


Bayern. Auf Entzug: Fehlende Behandlung für Heroinabhängige in Haft?

Heroinsucht gilt als schwere chronische Krankheit. Doch in bayerischen Gefängnissen werden Heroinersatzbehandlungen immer wieder abgebrochen. Experten kritisieren das scharf. (BR24, 28.10.2020)


Prevalence of Opioid Dependence and Opioid Agonist Treatment in the Berlin Custodial Setting: A Cross-Sectional Study. 

von Bernuth K, Seidel P, Krebs J, Lehmann M, Neumann B, Konrad N, Opitz-Welke A. 

Front Psychiatry. 2020 Aug 12;11:794. doi: 10.3389/fpsyt.2020.00794. PMID: 32903474; PMCID: PMC7435061.


Rapid upscale of depot buprenorphine (CAM2038) in custodial settings during the early COVID‐19 pandemic in New South Wales, Australia.

Roberts, J., White, B., Attalla, D., Ward, S., and Dunlop, A. (2020) 

Addiction. doi.org/10.1111/add.15244


OUD Care Service Improvement with Prolonged-release Buprenorphine in Prisons: Cost Estimation Analysis. 

Wright N, Hard J, Fearns C, Gilman M, Littlewood R, Clegg R, Parimelalagan L, Alam F. 

Clinicoecon Outcomes Res. 2020;12:499-504, doi.org/10.2147/CEOR.S256714


The Impact of Medications for Opioid Use Disorder on Hepatitis C Incidence Among Incarcerated Persons: A Systematic Review. 

Seval N, Wurcel A, Gunderson CG, Grimshaw A, Springer SA. 

Infect Dis Clin North Am. 2020;34(3):559-584. doi:10.1016/j.idc.2020.06.011


Hepatitis C in the criminal justice system: opportunities for global action in the era of viral hepatitis elimination. 

Akiyama MJ. 

BMC Med. 2020;18(1):208. Published 2020 Aug 14. doi:10.1186/s12916-020-01680-0


Optimizing the impact of medications for opioid use disorder at release from prison and jail settings: A microsimulation modeling study 

Macmadu A, Adams JW, Bessey SE, et al. 

[published online ahead of print, 2020 Jul 8]. Int J Drug Policy. 2020;102841. doi:10.1016/j.drugpo.2020.102841


Optimizing the impact of medications for opioid use disorder at release from prison and jail settings: A microsimulation modeling study 

Prisons: ignore them at our peril. 

Kamarulzaman A, Verster A, Altice FL. 

Curr Opin HIV AIDS. 2019;14(5):415-422. doi:10.1097/COH.0000000000000572

Prisons: ignore them at our peril. 

Reducing overdose after release from incarceration (ROAR): study protocol for an intervention to reduce risk of fatal and non-fatal opioid overdose among women after release from prison. 

Waddell EN, Baker R, Hartung DM, et al. 

Health Justice. 2020;8(1):18. Published 2020 Jul 10. doi:10.1186/s40352-020-00113-7

Reducing overdose after release from incarceration (ROAR): study protocol for an intervention to reduce risk of fatal and non-fatal opioid overdose among women after release from prison. 

Gesundheitsversorgung in Gefängnissen: Krank im Knast 

In deutschen Gefängnissen fehlt es an Geld, Personal und Medikamenten – mit teils dramatischen Folgen für die Häftlinge. (Die Tageszeitung, 04.08.2020)

Gesundheitsversorgung in Gefängnissen: Krank im Knast 

Risk factors for self-harm in prison: a systematic review and meta-analysis

Favril, Louis et al.

The Lancet Psychiatry, Volume 7, Issue 8, 682 - 691 


The Accessibility of Opioid Agonist Treatment and Its Forced Discontinuation in Swiss Prisons-Attitudes, Perceptions and Experiences of Defense Lawyers in Dealing With Detained Persons Using Opioids. 

Buadze A, Baggio S, Schleifer R, et al. 

Front Psychiatry. 2020;11:395. Published 2020 May 14. doi:10.3389/fpsyt.2020.00395


Prisoners should not be left behind in HCV research and policies. 

Moazen, B., Stöver, H., Dolan, K. et al. 

Harm Reduct J 17, 33 (2020). doi.org/10.1186/s12954-020-00379-y


Report. Global Prison Trends 2020

This year, PRI’s flagship publication Global Prison Trends, published alongside the Thailand Institute of Justice, has been released at a crucial time as prisons worldwide are being pushed to breaking point by the COVID-19 pandemic. Global Prison Trends 2020 documents the chronic issues that have led to this human rights and public health crisis and the challenges facing criminal justice systems in responding to the global pandemic. (PENAL REFORM INTERNATIONAL, UK, April 2020)


Implementation of opioid maintenance treatment in prisons in North Rhine-Westphalia, Germany - a top down approach.

Böhmer K, Schecke H, Render I, Scherbaum N.

Subst Abuse Treat Prev Policy. 2020 Mar 10;15(1):21. doi: 10.1186/s13011-020-00262-w.


Asistencial and therapeutic continuity after release from prison: an urgent problem that requires solutions. The model applied in Catalonian prisons.

Turu E, Barnés I, Marco A.

Rev Esp Sanid Penit. 2019;21(3):153-160.

PMID: 32083278


A study of the reasons for prescribing and misuse of gabapentinoids in prison including their co-prescription with opioids and antidepressants.

Soni A, Walters P.

Int J Prison Health. 2019 Aug 27;16(1):67-77. doi: 10.1108/IJPH-01-2019-0004.



Buprenorphin-Depot: Annäherung an das Äquivalenzprinzip in Haft - Besondere Eignung von Buvidal® zur Substitutionstherapie in der JVA 

Mannheim/Lund, 13.12.2019 – Die 4. Gefängnismedizintage am 5. und 6. Dezember 2019 in Frankfurt stießen auf reges Interesse bei Medizinern und Pflegekräften im Vollzug. Dem von der Camurus GmbH unterstützten Symposium „Das Depot – neue Wege in der Behandlung der Opioidabhängigkeit im Justizvollzug“ wohnten etwa 200 Besucher*innen bei. Mit der wachsenden Verfügbarkeit des Buprenorphin-Depots in Justizvollzugsanstalten kann eine deutliche Annäherung an das geforderte Äquivalenzprinzip erreicht werden, so ein Fazit der Referate und nachfolgenden Diskussion. (Camurus, Mannheim/Lund, 13.12.2019)